The Hemodynes H1 viscometer is a fast, compact point-of-care device. It will be available from 2027 for labs, university hospitals, and CROs under Research Use Only.
Blood viscosity varies up to threefold from one patient to the next. Yet most diagnostic models still rely on a default estimate. The Hemodynes viscometer changes that by delivering a fast, actionable measurement at the point of care.
The Hemodynes H1 viscometer opens diagnostic and therapeutic perspectives across multiple specialties.
Paired with the hemodynamic modeling platform, the viscometer enables computation of a personalized FFR-CT integrating the patient's blood viscosity — for greater precision in intermediate stenoses.
Before, during, and after treatment: the viscometer supports plasmapheresis monitoring by directly measuring plasma viscosity. A research application aimed at optimizing treatment protocols.
Blood viscosity is an independent risk factor in many conditions: hyperviscosity syndromes, type 2 diabetes, renal failure, peripheral artery disease, atrial fibrillation. Bedside viscosity measurement opens the door to exploring its role as a biomarker for risk stratification and therapeutic monitoring.
The Hemodynes H1 viscometer will be available under Research Use Only (RUO).
< 1 mL sample volume · < 1 min measurement time · 1–60 cP range · Whole blood or plasma
Reach out to discuss your research needs, RUO terms, and explore a validation partnership.
Get in touch